6L9.F Stock Surges 2400% on XETRA: ViewRay Inc. May 2026

ViewRay, Inc. (6L9.F) delivered a stunning 2400% surge on XETRA today, closing at €0.025 after opening at just €0.001. The medical device manufacturer, which specializes in MRI-guided radiation therapy systems, saw trading volume spike to 3,500 shares—more than 12 times its average daily volume. This extreme move reflects the stock’s severe distress, with 6L9.F trading near historic lows. The company’s market cap sits at approximately €207 million, though the stock has collapsed 99.4% from its €4.60 year-high. Investors should approach this volatile healthcare play with extreme caution.

Understanding the 6L9.F Stock Price Explosion

The 2400% daily gain in 6L9.F stock reflects a technical bounce from rock-bottom levels rather than fundamental improvement. ViewRay opened at €0.001 and closed at €0.025, marking the day’s high. This represents a €0.024 change in absolute terms. However, context matters: the stock trades at just 0.54% of its 50-day average price of €0.319, and 1.8% of its 200-day average of €2.717. The year-high of €4.60 seems distant now. Trading volume of 3,500 shares dwarfs the typical 279 shares daily average, indicating forced liquidations or speculative repositioning rather than institutional confidence in the business.

Meyka AI rates 6L9.F with a grade of C+, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

6L9.F Analysis: Financial Metrics Paint a Bleak Picture

ViewRay’s fundamentals reveal why 6L9.F stock has cratered so severely. The company posted a negative EPS of -€0.55 and carries a negative PE ratio, indicating ongoing losses. Revenue per share stands at just €0.566, while net income per share is -€0.594. Operating cash flow per share is -€0.508, and free cash flow per share is -€0.529—all deeply negative.

The balance sheet shows some resilience: cash per share of €0.752 and a current ratio of 2.36, meaning short-term liquidity remains adequate. However, debt-to-equity stands at 1.05, indicating the company carries substantial leverage. Return on equity is -85.2%, and return on assets is -39.5%. The price-to-sales ratio of 2.38 appears reasonable on the surface, but it masks the underlying cash burn. Track 6L9.F on Meyka for real-time updates on this distressed medical device stock.

Market Sentiment: Trading Activity and Liquidation Signals

Trading Activity: The spike in 6L9.F stock volume to 3,500 shares from an average of 279 signals forced repositioning. Relative volume reached 12.5 times normal levels, suggesting margin calls or portfolio rebalancing rather than organic buying interest. The stock’s extreme volatility—ranging from €0.001 to €0.025 in a single session—creates dangerous conditions for retail traders.

Liquidation Signals: ViewRay’s negative free cash flow of -€0.529 per share indicates the company burns cash operationally. With 8.29 billion shares outstanding, the company faces significant dilution risk if it must raise capital. The earnings announcement scheduled for May 9, 2024 (historical data) suggests management must address investor concerns about path to profitability. Healthcare sector peers trade at average PE ratios of 28.56, while 6L9.F’s negative multiple reflects deep distress.

ViewRay Inc. Stock: The MRI-Guided Radiation Therapy Story

ViewRay, Inc. designs and manufactures MRIdian systems—MRI-guided radiation therapy platforms for cancer treatment. Founded in 2004 and headquartered in Oakwood, Ohio, the company employs 295 people. CEO Paul Ziegler Jr. leads the organization as it serves university hospitals, community centers, and cancer clinics across the United States, France, Taiwan, and the United Kingdom.

The MRIdian technology addresses critical clinical challenges: beam distortion, skin toxicity, and treatment accuracy. This positions ViewRay in the high-growth medical devices sector. However, 6L9.F stock’s collapse suggests commercialization challenges, competitive pressures, or slower-than-expected adoption. The company’s research and development spending represents 31.7% of revenue, indicating heavy investment in innovation. Yet negative cash flows suggest revenue growth hasn’t kept pace with operating expenses.

Final Thoughts

ViewRay Inc. (6L9.F) experienced a 2400% daily surge, but this masks severe financial distress. The stock has collapsed 99.4% from its year-high, trading at €0.025 with negative earnings and significant cash burn. The massive 8.29 billion share count creates dilution risk. Meyka AI assigned a C+ grade with a HOLD recommendation. Extreme daily moves often signal liquidation rather than recovery. The company’s path to profitability remains unclear. Only experienced traders with high risk tolerance should consider this stock. Conservative investors should avoid it entirely.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.